Document is current
Any future updates will be listed below
-
Authors
Fonseca, Nicolette M.
Maurice-Dror, Corinne
Herberts, Cameron http://orcid.org/0000-0002-9929-8374
Tu, Wilson
Fan, William
Murtha, Andrew J. http://orcid.org/0000-0003-3980-7656
Kollmannsberger, Catarina
Kwan, Edmond M.
Parekh, Karan
Schönlau, Elena
Bernales, Cecily Q.
Donnellan, Gráinne
Ng, Sarah W. S. http://orcid.org/0000-0002-7647-6940
Sumiyoshi, Takayuki
Vergidis, Joanna
Noonan, Krista
Finch, Daygen L.
Zulfiqar, Muhammad
Miller, Stacy
Parimi, Sunil
Lavoie, Jean-Michel
Hardy, Edward
Soleimani, Maryam
Nappi, Lucia
Eigl, Bernhard J. http://orcid.org/0000-0003-1653-6929
Kollmannsberger, Christian
Taavitsainen, Sinja http://orcid.org/0000-0001-7559-9853
Nykter, Matti http://orcid.org/0000-0001-6956-2843
Tolmeijer, Sofie H. http://orcid.org/0000-0003-4066-885X
Boerrigter, Emmy http://orcid.org/0000-0002-3041-6774
Mehra, Niven http://orcid.org/0000-0002-4794-1831
van Erp, Nielka P.
De Laere, Bram
Lindberg, Johan
Grönberg, Henrik http://orcid.org/0000-0002-1073-2753
Khalaf, Daniel J.
Annala, Matti
Chi, Kim N.
Wyatt, Alexander W. http://orcid.org/0000-0003-2399-0329
-
Funding
Funding for this research was provided by:
Canadian Cancer Society Challenge Grant
- License Information
-
More Information
Article History
Received: 21 July 2023
Accepted: 24 January 2024
First Online: 28 February 2024
Competing interests
: C.M.D. reports Honoria from MSD, Bristol-Myers Squibb, Medison and Pfizer and consulting fees from Biomica LTD. E.M.K. has served in consulting or advisory roles in Astellas Pharma, Janssen, Ipsen and received honoraria from Janssen, Ipsen, Astellas Pharma, and Research Review. E.M.K. also reports research funding from Astellas Pharma (institutional) and AstraZeneca (institutional), and travel expense reimbursement from Astellas Pharma, Pfizer, Ipsen and Roche. K.N. has served on advisory boards for Abbvie, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Merck, Janssen and Tersera. D.L.F. has served in advisory roles or received honorarium from Janssen, Bayer, Astellas, AstraZeneca and Pfizer. M.A. is a shareholder in Fluivia Ltd. K.N.C. reports grants from Janssen, Astellas, and Sanofi during the conduct of the study. K.N.C. also reports grants and personal fees from Janssen, Astellas, AstraZeneca, and Sanofi, as well as personal fees from Constellation Pharmaceuticals, Daiichi Sankyo, Merck, Novartis, Pfizer, Point Biopharma, and Roche outside the submitted work. A.W.W. has served on advisory boards and/or received honoraria from AstraZeneca, Astellas, Bayer, EMD Serono, Janssen, Merck, and Pfizer. A.W.W.’s laboratory has a contract research agreement with ESSA Pharma. The remaining authors declare no competing interests.
